TNF and rheumatoid arthritis: In addition to the clinical efficacy in RA patients showing inadequate response to methotrexate (MTX) or TNF-inhibitors9–11, tofacitinib in combination with background MTX also prevents progression of structural damage in one-year follow-up12.